And the winner is …. Laurel Schunselaar
Laurel Schunselaar (LUMC) is the winner of the Paul Janssen Futurelab Nomination Letter 2019 for the best clinical proposal entitled ‘A phase Ib dose finding study with aclarubicin in patients with metastasized uveal melanoma.’ The letter will be submitted with the research proposal to ZonMw’s Rational Pharmacotherapy Program (GGG) for a half a million grant.
Schunselaar: “Aclarubicin seems to be a potent treatment for many different cancer types. We are first focusing on tumors for which there are few or no available treatments, like uveal melanoma and mesothelioma.”
From left: Ellen Kapiteijn, AG Jochemsen, Gre Luyten, Laurel Schunselaar, Sjaak Neefjes and Frank Speetjens
“It [the course] was very intensive but a lot of fun. The online and on-campus parts all fit well with my experience. My mentor during the extended course had a lot of experience with setting up phase 1 studies and it was very useful to brainstorm with her”, said Schunselaar about her participation in the Clinical Development course.
Articles from our blog
This may be interesting for you
And the winner is …. Dr. Hein Coolen
Dr. Hein Coolen of Fair Medicine is the winner of the Paul Janssen Futurelab Nomination Letter 2018 for the best clinical protocol entitled ‘A phase 2 Trial of monobenzone-imiquimod (MI) therapy in combination with nivolumab for the treatment of unresectable, Stage IIIB to IVM1c Melanoma’.
Janssen Pharmaceutica offers scholarships for biomedical start-ups for PJ Futurelab course
Janssen Pharmaceutica NV has made available 2 scholarships for the blended course Clinical Development from Paul Janssen Futurelab Leiden (PJ Futurelab). PJ Futurelab is a non-profit, independent education & training initiative of the Leiden University Medical Centre (LUMC) and Leiden University. Our mission is to train graduated biomedical professional to be tomorrow’s leaders in life sciences.
How to become a maker of tomorrow’s medicines using Real Options Theory
Paul Janssen Futurelab Leiden offers a new international blended education & training program for talented biomedical scientists on the development of novel medical interventions using the Real Options Theory. The aim is that these future chief scientific officers will change the entire drug development process.